Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Systemic Lupus Erythematosus (Proof-of-Concept)
2014-005000-19Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Ustekinumab with Placebo (2 arms). Primary endpoint: Composite SRI-4 Response at Week 24. Started Feb 2015; status: completed.
02
Drugs
ustekinumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2014-005000-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005000-19.